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introduction: Many antitumor therapies induce apoptotic cell death in order to cause 
tumor regression. Paradoxically, apoptotic cells are also known to promote wound heal-
ing, cell proliferation, and tumor cell repopulation in multicellular organisms. We aimed 
to characterize the nature of the regenerative signals concentrated in the micromilieu of 
dead and dying cells.
Methods: Cultures of viable melanoma B16F10 cells, mouse fibroblasts, and primary 
human fibroblast-like synoviocytes (FLS) in the presence of dead and dying cells, their 
supernatants (SNs), or purified agonists and antagonists were used to evaluate the stim-
ulation of proliferation. Viable cell quantification was performed by either flow cytometry 
of harvested cells or by crystal violet staining of adherent cells. High-performance liquid 
chromatography and liquid chromatography coupled with mass spectrometry of cell 
SNs were deployed to identify the nature of growth-promoting factors. Coimplantation 
of living cells in the presence of SNs collected from dead and dying cells and specific 
agonists was used to evaluate tumor growth in vivo.
results: The stimulation of proliferation of few surviving cells by bystander dead cells 
was confirmed for melanoma cells, mouse fibroblasts, and primary FLS. We found that 
small soluble molecules present in the protein-free fraction of SNs of dead and dying 
cells were responsible for the promotion of proliferation. The nucleoside inosine released 
by dead and dying cells acting via adenosine receptors was identified as putative inducer 
of proliferation of surviving tumor cells after irradiation and heat treatment.
conclusion: Inosine released by dead and dying cells mediates tumor cell proliferation 
via purinergic receptors. Therapeutic strategies surmounting this pathway may help to 
reduce the rate of recurrence after radio- and chemotherapy.
Keywords: melanoma, adenosine receptor, inosine, proliferation, repopulation, apoptosis, necrosis
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inTrODUcTiOn
In cancer therapy, most of the treatments aim to induce death of 
the malignant cells. Apoptosis has been reported as an ongoing 
mechanism during cancer treatment (1), and necrosis is also a 
common finding after various types of antineoplastic actions 
(2, 3). Causing massive cell death in solid tumors changes dra-
matically the tumor microenvironment and triggers biological 
reactions in the host and tumor (4). In multicellular organisms, 
dying cells require swift recognition and efficient removal by a 
process known as clearance of apoptotic cells (5). This event is 
habitually coupled with regeneration and healing processes and 
contributes to the restitution of the damaged organ. Before the 
clearance of apoptotic cells begins, dying cells release a plethora 
of “find me” signals that facilitate their prompt removal by 
phagocytes (6). Among “find me” signals reported to date count 
the nucleotides ATP and UTP (7), lysophosphatidylcholine (8), 
fractalkine (CX3CL1) (9), and sphingosine 1-phosphate (10).
Apoptosis also plays a pivotal role in tumor cell repopula-
tion (11) and in demodulation of antitumor responses (12, 13). 
Animals inoculated with a mixture of viable and irradiated 
(X-rays) tumor cells exhibited, already over 50 years ago, a reduc-
tion of the survival time and an enhancement of tumor growth 
(14). More recently, several apoptosis-related regeneration phe-
nomena have been reported. β-Catenin-directed Wnt signaling is 
involved in the compensatory proliferation after apoptotic stimuli 
in lower multicellular organisms (15). Stroma cells derived from 
human cancer promote the tumor progression after radiotherapy 
by the paracrine action of another member of the Wnt family, 
Wnt16B (16). The most convincing evidence so far includes 
PGE2 released by dying tumor cells in a caspase 3-dependent 
manner as a potent growth-stimulating factor that may support 
tumor repopulation after radiotherapy (17). Our studies showing 
the growth of melanoma cells by irradiated homologous cells 
confirm that apoptosis is involved in the compensatory prolif-
eration of neighboring surviving cells (18). However, the role of 
further “find me” signals released by tumor cells killed by chemo- 
or radiotherapy in the repopulation of tumors is controversial 
and needs to be clarified.
All these mediators are expected, in the first place, to establish 
a gradient for phagocyte attraction (6). However, some of them 
lack stability to reach long-range targets and their effects may be 
more important locally on surviving sister cells. Nucleotides are 
unlikely to serve as long-range “find me” signals to phagocytes 
since they are readily degraded by extracellular nucleotidases 
(19). The most important ectonucleotidases CD73 and CD39 are 
expressed ubiquitously in the human organism and especially on 
tumor cells (20, 21). Nucleotides are, therefore, considered the 
main source of extracellular nucleosides in the tumor microenvi-
ronment and the concentrations of adenosine range from 0.2 to 
2.4 μM (22). The effects of the second messenger adenosine are 
pleiotropic and widespread (23) and have been associated with 
the promotion of tumor growth but until now indirectly through 
its effects on the adaptive immune system (24).
Since B16F10 melanoma cells readily respond with enhanced 
proliferation in the absence of immune cells in vitro when they are 
stimulated with dead and dying homologous cells (18), we aimed 
to identify the factors produced by dead and dying cells responsible 
for this effect. First, we ascertained that the factor promoting 
proliferation is a non-proteic metabolite released by dead and 
dying cells. Employing high-performance liquid chromatography 
(HPLC) analysis we measured significant amounts of ATP and 
inosine but not adenosine in protein-free supernatants (SNs) 
of irradiated melanoma cells. Assays with purified purinergic 
agonists and antagonists confirmed that inosine induces potent 
stimulation of tumor cell proliferation via adenosine receptors.
MaTerials anD MeThODs
reagents and Media
Dulbecco’s Modified Eagle’s Medium (DMEM), Roswell Park 
Memorial Institute 1640 medium (RPMI 1640), fetal bovine 
serum (FBS), penicillin–streptomycin, and glutamine were pur-
chased from Gibco (Thermo Fisher, Germany). Trypsin-EDTA 
solution, adenosine, inosine, AMP, ADP, and ATP, the A2b 
(alloxazine) and A3 adenosine receptors (VUF5574), and caf-
feine, a non-selective adenosine antagonist, were purchased from 
Sigma-Aldrich (Germany). The antagonists for A1 (DPCPX) 
and A2a (SCH-58261) adenosine receptors were purchased from 
Tocris, UK.
cell lines and culture conditions
The C57Bl/6 mouse-derived melanoma cell line B16F10 was 
purchased from ATCC (#CRL-6475) and propagated in DMEM 
supplemented with 10% FBS and penicillin/streptomycin (D10) 
at 37°C in a 5% CO2 atmosphere. NIH/3T3 fibroblast cell line 
was purchased from ATCC (#CRL-1648) and cultured in RPMI 
1640 supplemented with 10% FBS, streptomycin/penicillin, and 
glutamine (R10). Human synovial tissue samples were obtained 
from knee joints of patients with rheumatoid arthritis from 
the orthopedic rheumatology unit of the Waldkrankenhaus St. 
Marienin Erlangen. An informed consent was obtained from 
patients, and their use was approved by the local ethics committee 
(Permit # 52_14B_3). Human fibroblast-like synoviocytes (FLS) 
were dissected by cutting off the villi of the synovial membrane. 
The tissue was digested using Collagenase IV solution (Sigma) in a 
shaking thermomixer at 37°C in two steps for 45 min. The samples 
were vortexed vigorously to release the cells. The collected cells 
were allowed to adhere to culture flasks for 2 days, with addition 
of fresh medium every day. Then, complete medium was removed 
together with non-attached cells, and cells were washed rigor-
ously. Adherent cells were a mixture of two major cell subtypes: 
type A macrophage-like and type B FLS. Short trypsinization 
steps of about 2 min at each passage allow detachment of only 
fibroblastic-like cells and thereby removal of the monocytic cells 
from the cell mixture. The terminally differentiated macrophages 
have a limited life span in  vitro, which contributes to the for-
mation of a relatively clean pool of FLS. The isolated FLS were 
expanded in culture flasks for three passages by splitting them in a 
1:2 ratio at confluency. The cells were used for proliferation assays 
in passages 3–6 in R10 medium supplemented with 1% fungizone 
(Gibco). Viable cells were seeded in 24-well plates at very low 
densities (200–1,000 cells/well) in the presence of dead and dying 
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cells or their SNs. Control wells containing only 200 B16F10 cells 
in D10, 1,000 FLS in R10, or in indicated SN were included in 
the same plate during one experiment. Agonists, antagonists, 
and vehicle were added as indicated. Transwell experiments were 
performed with ThinCerts™ cell culture inserts from Greiner 
Bio-One employing a 0.4  µm pore size membrane on 24-well 
plates (Greiner Bio-One, Germany).
cell Death induction and  
sn Preparation
Cell death was induced by irradiation with ultraviolet light type 
B (UVB) at 1.5 mJ/cm2/s or by heat shock (56°C for 30 min). The 
phenotype of cells after cell death induction was confirmed by 
a morphophysiological classification by flow cytometry (25) as 
previously shown [see Figures 2E,F in Ref. (13)]. At the indicated 
time points, SNs were collected, centrifuged at 6,000 g for 10 min, 
stored at −70°C until further use, and thawed only once. When 
necessary, the SNs were boiled on water bath for 15  min for 
deproteinization. A further protein-free fraction was obtained 
by filtration through Amicon® (Millipore, Germany) filters with 
a 3 kDa size cutoff membrane.
hPlc and Mass spectrometry
High-performance liquid chromatography and size exclusion 
chromatography (HPLC–SEC) were performed with a Perkin 
Elmer Series 200 HPLC system using Strong Cation Exchange 
(SCX) column purchased from Shiseido CAPCELL PAK SCX UG 
5 µm 150 mm × 1.5 mm. The protocol for detection of adenosine 
was developed based on manufacturer’s recommendations. 
The data was recorded for 10 pps and at 254 nm on column 
data with a 50 mM potassium dihydrogen orthophosphate 
(KH2PO4)– dipotassium hydrogen orthophosphate (K2HPO4) 
buffer (pH = 2.6) as a mobile phase and a flow rate of 0.5 ml/min 
(~860 psi) detection (26). The quantification of the concentration 
of purinergic metabolites was performed by liquid chromatogra-
phy coupled with mass spectrometry.
Measurement of cell Proliferation
Cell cultures were harvested at the indicated time points by 
collecting the medium containing dead and spontaneously 
detached cell together with adherent cells after treatment with 
trypsin-EDTA solution for 20 min. Cell growth was quantified at 
different time points by flow cytometry employing a Gallios flow 
cytometer (Beckman-Coulter, Miami, FL, USA). Only viable cells 
excluding propidium iodide were recorded. Since the harvesting 
procedure required prolonged incubation and pipetting steps, an 
alternative colorimetric method for the quantification of growth 
was established for experiment requiring multiple simultane-
ous harvesting (27). Briefly, dead and non-adherent cells were 
washed out with warm PBS; adherent cells were fixed for 30 min 
in a solution of glutaraldehyde (1% in PBS), washed with PBS 
(pH 7.4), and subsequently stained with a 0.01% crystal violet 
solution (in 20% methanol). After removing excess of dye, the 
crystal violet-stained cells were dissolved in 1 ml of a 10% sodium 
dodecyl sulfate solution, and the optical density of the extracted 
dye was read in a spectrophotometer at 590 nm (27).
In Vivo Tumor cell growth
Wild-type C57Bl/6 mice were bred at the Institute of Cell Biology, 
Lviv, Ukraine and kept on a standard diet with drinking water 
available ad  libitum. A total of 5 ×  105 viable cells in Ringer’s 
solution, with adenosine or with SNs of dying cells (four mice 
per group), were implanted subcutaneously on the back of each 
mouse. Tumor volume was measured using a caliper from the 
day of appearance until the end of the experiment. Animal stud-
ies were conducted according to European principles and local 
guidelines for the care and use of laboratory animals. Experiments 
were performed on mice matched for age and sex and evaluated 
with blinded identity.
statistical analysis
Data are reported as mean ±  standard error of replicate mean 
values. The software package GraphPad Prism 5.0 was used for 
graphics and statistical tests. For comparisons between control 
and experimental groups, Mann–Whitney U test or two-way 
ANOVA tests were employed as appropriate. Statistical signifi-
cance was assumed if p < 0.05.
resUlTs
stimulation of cell Proliferation  
by Bystander Dead cells, the  
“Feeder cells” effect
In order to simulate the conditions during cancer treatment 
where the vast majority of tumor cells are killed by irradiation 
and only a few survive, we evaluated the growth of few viable 
B16F10 cells (200 cells/well) in the presence of higher quantities 
of dying cells killed by UVB irradiation (apoptosis induction). 
Cultures were kept without adding fresh medium during the 
whole indicated culture period. Dying cells alone and viable 
cells alone were cultured simultaneously in separate wells as 
controls. We observed that cocultures of viable cells with dying 
cells by apoptosis supported rapid growth of viable cells seeded 
at very low densities. Seeding cells at these densities in D10 
medium only showed no proliferation during the same period 
of time (Figure  1A). This effect was more pronounced when 
lower numbers of dying cells reach a maximum at the viable/
dead cell ratio of 1:100 (Figure 1B). When the number of dead 
cells was further increased, the promotion of proliferation was 
completely abolished (Figure 1B). In order to explore whether 
physical contact between viable and dying cells is necessary 
to trigger cell growth enhancement, viable B16F10 cells were 
cultured in transwell plates (ThinCert Greiner, Germany), 
which allow physical separation of cells by a 0.4  µm pore 
membrane. Viable cells were plated in the upper side of the 
transwell, and 100 times more dying cells were placed in the 
lower compartment. The promotion of proliferation was also 
achieved when dying cells were separated from the viable ones 
(Figure 1C), indicating that soluble stimulating factors released 
by dead and dying cells concur to promote melanoma cell 
proliferation.
In order to elucidate whether the promotion of prolifera-
tion was specific for the melanoma cell line, we also employed 
FigUre 1 | stimulation of tumor cell proliferation by bystander dying cells, the “feeder cells” effect. The upper panel shows viable cell counts of 
cocultures [closed circles in panels (a–c)] and viable cells alone in D10 medium [open circles in panels (a–c)]. Cocultures were composed of viable (200 cells/well) 
and lethally ultraviolet light type B-irradiated (10,000 cells/well) B16F10 melanoma cells (a). Dead/viable ratio titration of cocultures (B). Transwell cocultures with 
10,000 apoptotic cells (c). The lower panel shows cell counts of independent wells containing fibroblasts in R10 medium [open circles in panels (D–F)] or in 
supernatants (SN) from apoptotic cells [closed circles in panels (D–F)]. Mouse NIH/3T3 fibroblast (1,000 cells/well) cultures with SNs of 0.2 million cells/ml apoptotic 
homologous cells (D). Human fibroblast-like synoviocytes (FLS, 1,000 cells/well) from two rheumatoid arthritis patients RA315 (e) and RA314 (F) cocultured with 
SNs from apoptotic neutrophils (0.2 million cells/ml).
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NIH/3T3 mouse fibroblasts cultured with SNs from apoptotic 
homologous cells. Employing the staining method for adherent 
cells we quantified proliferation more efficiently as with the flow 
cytometric method and observed that the conditioned medium 
from irradiated fibroblast significantly stimulated the prolif-
eration compared to fibroblasts cultured in R10 medium alone 
(Figure 1D). Furthermore, the source of the stimulatory potential 
and the proliferating target cell were not limited to immortalized 
cells. Primary FLS from patients with rheumatoid arthritis were 
also stimulated to proliferate by SNs of apoptotic neutrophils 
(Figures 1E,F).
Dying and Dead cells release 
Proliferation-stimulating Factors
The analysis of SNs collected at different time points after the 
induction of cell death showed that cells dying by apoptosis after 
irradiation released the stimulating factors after 12 h of culture 
and lasted for 36  h more (Figure  2A). In contrast, heat shock 
treatment resulted in immediate necrosis and release of prolifer-
ation-stimulating factors (Figure 2B). In order to investigate the 
nature of the released factors, we boiled SN collected after 24 h of 
irradiation and after 8 h of heat shock treatment and compared 
the stimulating capacity with that of untreated SNs and fresh 
D10 medium. We found that boiling only partially reduced the 
stimulating capacity of the SNs from both apoptotic (Figure 2C) 
and necrotic cells (Figure 2D). These results suggest that proteins 
released after cell death are unlikely to be responsible for the 
stimulation of proliferation in melanoma cells. We confirmed this 
hypothesis when we prepared the protein-free and -rich fractions 
by filtration through a 3 kDa membrane of SNs and medium. We 
observed that the proliferation-stimulating activity was present 
only in the protein-free fraction of dead cell SNs (Figures 2E,F). 
Interestingly, cells proliferated even in the absence of high 
molecular weight nutrients, which rather represents a starving 
condition.
Molecular analysis of the Protein-Free 
Fraction of sns from Dying cells
One of the most important non-proteic metabolites released is 
the nucleotide ATP. Therefore, we set up a HPLC–SEC analysis 
of the composition of protein-free fractions of SNs from dying 
cells contrasted with the standards ATP, adenosine, and inosine. 
The runs for two samples of SNs and fresh medium are shown 
in Figure 3A, upper panel. The purified standards are shown in 
the lower panel (Figure 3A). The chromatographic separation of 
the metabolites allows speculating about ATP and inosine being 
present in the SNs of dying cells. The same is not true for adeno-
sine. The mass spectrometric analysis confirmed the presence of 
inosine (10 nM) or its metabolite hypoxanthine (10 nM) in SNs of 
apoptotic and necrotic cells, respectively (Figure 3B). Adenosine 
was detectable but at much lower concentration (<0.2  μM; 
Figure  3B). Adenosine in the body is produced by the action 
of ectonucleotidases from nucleotides like ATP, ADP, and AMP. 
Adenosine is either immediately transported to the intracellular 
space or is degraded by the action of adenosine deaminase into 
inosine (28). The phosphorylation of the ribose from the inosine 
FigUre 2 | apoptotic and necrotic cells release proliferation-stimulating factors. Shown are cell counts of cultures of viable cells in medium alone (open 
circles) or in supernatants (SNs) from dead and dying cells (closed circles). Factors stimulating proliferation are released by dying and dead cells after 12 h of 
irradiation [apoptosis (a)] and immediately after heat shock [necrosis (B)]. Proliferation was measured by the crystal violet assay for adherent cells. Boiling of SNs 
(half-full circles) partially reduces but not abolishes the stimulation of proliferation of tumor cells [24 h after irradiation (c) and 1 h after heat shock (D)]. Factors 
stimulating the proliferation of tumor cells are present in the protein-free fraction (e) and not in the protein-rich fraction (F) of dead cell SNs.
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results in the generation of hypoxanthine and ribose-1-PO4 (29). 
We confirmed that all these steps of the purinergic metabolism 
take place spontaneously in cell-free SNs. The addition of 500 µM 
purified adenosine to cell-free SNs from dying cells resulted in 
the clearance of adenosine and the production of inosine and 
hypoxanthine (Figure  3C). These results confirm that nucleo-
tides are released by dying cells and are immediately catabolized 
by ectonucleotidases present in the culture into adenosine and 
inosine.
adenosine receptors Mediate the 
stimulation of the Proliferation induced  
by sns of Dead and Dying cells
After confirming the presence of inosine and ATP as major 
purinergic metabolites in the SN of both apoptotic and necrotic 
cells, we investigated the relative potency of the purified nucleo-
tides ATP, ADP, and AMP (Figure 4A) and nucleosides adenosine 
and inosine (Figure 4B) after 9 days of culture of melanoma cells 
FigUre 3 | Molecular analysis of the protein-free fraction of supernatants (sns) from dying cells. Electrograms of SNs of B16F10 cells after 24 h of 
irradiation and metabolite standards by high-performance liquid chromatography (a). Concentrations of nucleosides measured by mass spectrometry of SNs of 
B16F10 cells after 24 h of irradiation and 1 h after heat shock (B). Spontaneous adenosine degradation into its metabolites inosine and hypoxanthine in SN spiked 
with 500 µM of adenosine and measured by mass spectrometry (c).
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without feeding. Nucleotides begin to exert stimulating activity 
at 10  µM concentrations (Figure  4A), whereas nucleosides 
stimulate proliferation at 50  µM concentration (Figure  4B). 
Both types of metabolites exhibited a bell-shaped dose–response 
curve similar to that observed for dead/viable cells cocultures 
(Figure 1B).
In order to investigate whether adenosine receptors par-
ticipate in the stimulation of proliferation induced by purinergic 
metabolites, we added the pan-adenosine receptor antagonist 
caffeine and the specific adenosine receptor antagonists alloxa-
zine (A2bR) and VUF (A3R) to adenosine-stimulated cultures 
and observed that the stimulation of proliferation most likely 
mediated by inosine was abolished in the presence of the antago-
nists for the adenosine receptors A2b and A3 and not by the 
antagonists of the receptors A1 and A2a (Figure 4C). Additionally, 
we confirmed the expression of the adenosine receptors A1, 
A2b, and A3 on the surface of viable B16F10 melanoma cells 
(Figure 4D).
stimulation of Proliferation In Vivo
The implantation of few (50,000) B16F10 cells in the subcutane-
ous space of the back of C5Bl/6 mice led to the late development 
of solid tumors. The first measurable tumor appeared at day 24 
after implantation (Figure  5, black line). Coimplantation with 
either SNs from apoptotic cells or with 200 µM adenosine caused 
the development of larger tumors (Figure 5, colored lines).
DiscUssiOn
During tissue turn over, dying cells are swiftly cleared by innate 
immune sentinels in a silent manner (30). Many conditions 
of health and disease are clearly modulated by the presence 
and effects of apoptotic cells (31). The induction of tumor cell 
death is a central goal of chemo- and radiotherapy. Therefore, 
the understanding of modulatory signals from dying and 
dead cells might be important for clarifying some undesirable 
outcomes after cancer therapy (32, 33). The first observation 
FigUre 4 | adenosine receptors mediate the stimulation of the proliferation induced by supernatants of dead and dying cells. Shown are cell counts  
of cultures measured by the crystal violet method for adherent cells at day 9 showing the relative potency of nucleotides (a) and nucleosides (B) on the stimulation 
of proliferation of B16F10 melanoma cells (D10 medium wells are open circles, purinergic metabolites are closed circles, and vehicles for adenosine are gray circles). 
The pan-adenosine receptor antagonist caffeine and the specific adenosine receptor antagonists alloxazine (A2bR) and VUF (A3R) blocked the stimulation of 
proliferation induced by inosine (c). Adenosine receptor expression on B16F10 cells (D). Green represent the isotype antibody binding and red the receptor 
antibody.
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about signals derived from dying cells supporting either cell 
proliferation or tumor growth came from early works of Revesz in 
1956 on mammary carcinoma C3H cells killed by X-rays (14). 
By that time, it was referred as “a feeder effect in which the dead 
cells released essential nutrients.” Currently, it is well known that 
apoptotic cells possess regenerative properties. A potentially 
important aspect of the called “feeder effect” of apoptotic cells in 
the tumor microenvironment is their capacity to activate com-
pensatory proliferative responses in their neighborhood (34). 
The basis for this potential lies in responses to wounding, notably 
in Drosophila, Xenopus, and Hydra. The molecular mechanisms 
underlying the proliferative responses elicited by dying/dead cells 
are far from clear and include Wnt and MAPK signaling (35). 
We have previously reported that the growth-promoting factors 
are released by apoptotic B16F10 melanoma cells and acted at 
remote sites in an in vivo model of tumor growth (18). However, 
all these findings only partially explained the observed regenera-
tion phenomena and were limited to irradiated cells or wound 
healing (15–17). In this work, we describe the particular features 
of proliferation-promoting factors that lead us to identify inosine 
FigUre 5 | stimulation of proliferation in vivo. The presence of 
adenosine or supernatant of irradiated cells at the site of implantation  
of 50,000 B16F10 cells caused development of larger subcutaneous  
tumors in C57Bl/6 mice (n = 6 per group).
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as a putative main mediator of tumor repopulation after massive 
death of tumor cells.
One of the most important features of the proliferation-
supporting activity is its restriction to a range of concentrations. 
High and very low densities of dying/dead cells did not stimulate 
cell proliferation in  vitro. Adverse conditions are known to be 
present in SNs of dying/dead cells (36) and may explain why high 
densities of dying cells have deleterious effects for cell prolifera-
tion. The induction of proliferation of viable cells also occurred 
when dead ones were physically separated, confirming the soluble 
nature of the factor derived from dead cells. This observation sup-
ports previous findings, where dying cells implanted at distant 
location from viable also promoted the growth of tumors in vivo 
(18). Finally, the fractionation of SN of necrotic cells resulted in 
stimulation of proliferation in conditions that otherwise resulted 
in death by starvation. Based on these observations, we propose 
here for the first time that both apoptotic and necrotic cells 
promote the stimulation of proliferation of viable cells mainly 
through the release of soluble factors. This is in line with the idea 
of a highly conserved homeostatic mechanism driven by dead/
dying cells to maintain the homeostasis of an organ.
In order to further characterize the nature of the stimulating 
signal, we killed cells with increasing temperatures and observed 
that the effect persists at 70°C (data not shown). Furthermore, 
SNs of dying cells boiled at 100°C for 15 min were still able to sup-
port cell proliferation of viable cells. These observations clearly 
support the involvement of non-proteic bioactive molecules in 
the stimulation of proliferation released from dead and dying 
cells. The most important chemotactic mediators released by 
apoptotic cells are ATP (7) and adenosine (12). Therefore, we 
narrowed the molecular analysis of the SNs by HPLC–SEC and 
mass spectrometry to purinergic metabolites. We found traces of 
ATP and inosine but not adenosine in the SNs of apoptotic cells. 
Since ectonucleotidases and adenosine deaminase are broadly 
expressed in neoplastic and normal cells, we assume that released 
ATP can be rapidly transformed to ADP, AMP, adenosine, and 
inosine in the SN. We confirmed this assumption by adding 
adenosine to an apoptotic cell SN and incubating for 48 h. The 
transformation of adenosine to inosine suggests the presence of 
active adenosine deaminase in the SNs of apoptotic cells.
The concentrations of inosine or hypoxanthine measured in 
the SNs of apoptotic and necrotic cells roughly reflect the minimal 
amount of purified inosine required to induce proliferation in 
melanoma cells. Adenosine has reportedly growth-promoting and 
growth-inhibitory effects depending on the tumor type (37–39). 
We could only verify the stimulating capacity of adenosine in 
our system, and it seems to be limited by the concentration of 
the adenosine vehicle ammonia. It has already been reported that 
inosine, and not adenosine, exerts potent proliferation-stimulatory 
actions on melanoma cells, mainly through the engagement of A3 
adenosine receptor (40). Since we have not inhibited the catabolism 
of adenosine to inosine in the SNs, it is likely that the stimulation of 
proliferation of melanoma cells is ultimately supported by inosine. 
The specific inhibition of adenosine receptors on melanoma cells 
further confirms that inosine is an important stimulator of cell 
proliferation and may act as a mediator of the healing and repopu-
lation processes subsequent to massive cellular damage.
The generation of larger tumors in vivo during the same time 
frame and starting from the same amount of regenerating cells 
supports the hypothesis that the presence of purinergic metabo-
lites in the micromilieu surrounding surviving tumor cells plays a 
decisive role in the outcome of the applied therapy, especially if cell 
death has been massively induced. Concentrations of nucleosides 
in the microenvironment of solid tumors have been rarely meas-
ured. In solid carcinomas, the concentrations of adenosine ranged 
from 0.2 to 2.4 μM and were significantly higher than healthy 
tissues (22). Interestingly, various types of cancers express adeno-
sine receptors, for example, A1, A2a, and A3 adenosine receptors 
have been found in human colorectal carcinoma (41–43), human 
leukemia Jurkat T cells (44), F98 glioblastoma cells (45–47), and 
melanoma cells (48, 49). The adenosine receptor A2b has also 
been found in melanoma cells (50) and is strongly associated with 
neovascularization of tumors. Our results provide a novel link 
between induction of cell death and the release of potent stimula-
tors of cell proliferation that can be exploited by surviving cells. A 
systematic measurement of nucleosides (51), especially inosine, in 
the microenvironment of solid tumors in combination with tumor 
progression data may contribute to improve the prognosis of can-
cer patients. Therapeutic interventions leading to cause tumor cell 
death may take advantage of the enormous progress been made in 
the pharmacology of adenosine receptor targeting (23).
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